Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer

Journal of Clinical Oncology

Volumn 26, Issue 32, 2008, Pages 5261-5268

  Machiels, Jean Pascal ^a   Mazzeo, Filomena ^b   Clausse, Marylene ^b   Filleul, Bertrand ^b   Marcelis, Luc ^b   Honhon, Brigitte ^b   D'Hondt, Lionel ^b   Dopchie, Catherine ^b   Verschaeve, Vincent ^b   Duck, Lionel ^b   Verhoeven, Didier ^b   Jousten, Peter ^b   Bonny, Marie Alix ^b   Moxhon, Anne Marie ^b   Tombal, Bertrand ^b   Kerger, Joseph ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ANEMIA; ARTICLE; CANCER PATIENT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGITIS; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT RESPONSE; VEIN THROMBOSIS; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BELGIUM; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREDNISONE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 55949089682     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.9524     Document Type: Article

References (29)

1. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 35:1502-1512, 2004
2. Berthold DR, Pond GR, Soban F, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 26:242-245, 2008
3. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced prostate cancer. N Engl J Med 35:1513-1520, 2004
4. Kantoff PW, Halabi S, Conaway M, et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17:2506-2513, 1999
5. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996
6. Oudard S, Banu E, Beuzeboc P, et al: Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23:3343-3351, 2005
7. Benson R, Hartley-Asp B: Mechanisms of action and clinical use of estramustine. Cancer Invest 8:375-380, 1990
8. Perry CM, McTavish D: Estramustine phosphate sodium: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 7:49-74, 1995
9. Kreis W, Budman DR, Calabro A: Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 79:196-202, 1997
10. Williams JF, Muenchen HJ, Kamradt JM, et al: Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: An experimental study. Prostate 44:275-278, 2000
11. Oudard S, Legrier ME, Boye K, et al: Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 169:1729-1734, 2003
12. Hamilton A, Muggia F: Estramustine potentiates taxane in prostate and refractory breast cancers. Oncology 15:S40-S43, 2001 (suppl 7)
13. Sinibaldi VJ, Carducci MA, Moore-Cooper S, et al: Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 94:1457-1465, 2002
14. Weitzman AL, Shelton G, Zuech N, et al: Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 163: 834-837, 2000
15. Savarese DM, Halabi S, Hars V, et al: Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. J Clin Oncol 19:2509-2516, 2001
16. Boehmer A, Anastasiadis AG, Feyerabend S, et al: Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: A single-center experience. Anticancer Res 25:4481-4486, 2005
17. Sitka Copur M, Ledakis P, Lynch J, et al: Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol 28:S16-S21, 2001 (suppl 15)
18. Eymard JC, Priou F, Zannetti A, et al: Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 18:1064-1070, 2007
19. Caffo O, Sava T, Comploj E, et al: Docetaxel and estramustine as first-line chemotherapy for patients with hormone-refractory advanced prostate cancer: Final results of a multicentric phase II randomized trial. J Clin Oncol 25:654s, 2007 (suppl; abstr 15552)
20. Fizazi K, Le Maitre A, Hudes G, et al: Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: A meta-analysis of individual patient data. Lancet Oncol 8:994-1000, 2007
21. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467, 1999
22. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:102-115, 1975
23. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
24. Fayers P, Bottomley A: Quality of life research within the EORTC: The EORTC QLQ-C30. Eur J Cancer 38:125-133, 2002
25. Fayers P, Aaronson NK, Bjordal K, et al: EORTC QLQ-C30 Scoring Manual (ed 3). Brussels, Belgium, European Organisation for Research and Treatment of Cancer, 2001
26. Armstrong AJ, Garrett-Mayer E, Yang Y, et al: Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25:3965-3970, 2007
27. Petrylak DP, Ankerst DP, Jiang CS, et al: Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98:516-521, 2006
28. Petrylak DP, Shelton GB, England-Owen C, et al: Response and preliminary survival results of a phase II study of docetaxel (D) + estramustine (E) in patients (Pts) with androgen-independent prostate cancer (AIPCA). Proc Am Soc Clin Oncol 19:334s, 2000 (abstr 1312)
29. Bodin L, Verstuyft C, Tregouet DA, et al: Cytochrome P450 2C9 and vitamin K epoxide reductase genotypes as determinants of acenocoumarol sensitivity. Blood 106:135-140, 2005